369 related articles for article (PubMed ID: 27214873)
1. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
2. The Platin-X series: activation, targeting, and delivery.
Basu U; Banik B; Wen R; Pathak RK; Dhar S
Dalton Trans; 2016 Aug; 45(33):12992-3004. PubMed ID: 27493131
[TBL] [Abstract][Full Text] [Related]
3. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
Najjar A; Rajabi N; Karaman R
Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
[TBL] [Abstract][Full Text] [Related]
4. Multi-action Pt(IV) anticancer agents; do we understand how they work?
Gibson D
J Inorg Biochem; 2019 Feb; 191():77-84. PubMed ID: 30471522
[TBL] [Abstract][Full Text] [Related]
5. Platinum(IV) Prodrugs.
Venkatesh V; Sadler PJ
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
[TBL] [Abstract][Full Text] [Related]
6. Anticancer platinum (IV) prodrugs with novel modes of activity.
Chin CF; Wong DY; Jothibasu R; Ang WH
Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
[TBL] [Abstract][Full Text] [Related]
7. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
8. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
9. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
10. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
[TBL] [Abstract][Full Text] [Related]
11. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
13. The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.
Montaña AM; Batalla C
Curr Med Chem; 2009; 16(18):2235-60. PubMed ID: 19519389
[TBL] [Abstract][Full Text] [Related]
14. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
Gibson D
ChemMedChem; 2021 Jul; 16(14):2188-2191. PubMed ID: 33928760
[TBL] [Abstract][Full Text] [Related]
15. Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one.
Gabano E; Ravera M; Osella D
Dalton Trans; 2014 Jul; 43(26):9813-20. PubMed ID: 24874896
[TBL] [Abstract][Full Text] [Related]
16. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
17. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based drugs: past, present and future.
Dilruba S; Kalayda GV
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1103-24. PubMed ID: 26886018
[TBL] [Abstract][Full Text] [Related]
20. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]